Aspergillus InfectionNCT07440485
Aspergillus Infection in Patients Admitted to Hematology Ward
An observational study of Aspergillus Infection, run by Fondazione IRCCS Policlinico San Matteo di Pavia at 1 site in Italy.
Trial summary
Aspergillus is a filamentous mould ubiquitous in the environment and the concentration of its spores in the air varies according to weather conditions and seasons. In this regard, efforts are often made to limit its diffusion in wards where fragile patients are housed (e.g., ICU, Haematology, Oncology, etc.). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Aspergillus Infection
- How many people
- 193 participants
- Where
- 1 siteItaly
- Study dates
- 14 Feb 2024to 14 Mar 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients admitted to the Hematology ward
Who may be able to join
- ≥ 18 years old
- Signature of informed consent
- Admission to San Matteo's Hematology ward
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Italy1 site, 1 recruiting
- Recruiting
Fondazione IRCCS Policlinico San Matteo di Pavia
Pavia, Pavia, 27100
Alba Muzzi, 0382/502268, a.muzzi@smatteo.pv.it
About this study
Official title: A Prospective Study on the Incidence of Invasive Aspergillus Infections in Hematology Patients: the Utility of Nasal Swab Screening and Environmental Sampling (AspHem)
Aspergillus is a filamentous mould ubiquitous in the environment and the concentration of its spores in the air varies according to weather conditions and seasons. In this regard, efforts are often made to limit its diffusion in wards where fragile patients are housed (e.g., ICU, Haematology, Oncology, etc.). Indeed, in these patients, Aspergillus infections can present as pulmonary aspergillosis, invasive rhinosinusitis or angio-invasive aspergillosis with significantly high rates of morbidity and mortality, while it rarely causes disease in healthy immunocompetent subjects.
Previous studies have established the correlation between nasal carriage of microorganisms and the development of an invasive infectious disease; however, those studies mainly focused on Staphylococci and Candida species.
The main target of this study is to investigate the spread of Aspergillus within a hospital ward and analyse the correlation between nosocomial infection and symptom severity in a cohort of frail population.
- Conditions
- Aspergillus Infection
- Medical subject headings
- Aspergillosis
What is being measured
The primary outcome is the main question the study is designed to answer.
number of new onset of invasive aspergillosis
number of new onset of invasive aspergillosis in patients who entered the ward with a negative swab at admission over person-time.
Measured: up to 2 years
Secondary outcomes (1)
correlation between the levels of Aspergillus in the air and the number of subjects with a positive swab at discharge
Measured: up to 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Feb 2026
- Study start14 Feb 2024
- Primary completion14 Mar 2026 (estimated)
- Study completion14 Mar 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Aspergillus InfectionStudies of the same condition, open and under way.
- More trials run by Fondazione IRCCS Policlinico San Matteo di PaviaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 193 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Alba Muzzi, Fondazione IRCCS Policlinico San Matteo di Pavia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07440485
- Sponsor's protocol ID
- AspHem
- Status last verified
- Feb 2026
- First submitted
- 23 Feb 2026
- Last updated
- 27 Feb 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Study on the Incidence of Invasive Aspergillus Infections in Hematology Patients: the Utility of Nasal Swab Screening and Environmental Sampling (AspHem)
- ClinicalTrials.gov ID
- NCT07440485
- Acronym / sponsor ID
- AspHem
- Conditions
- Aspergillus Infection
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 193 participants (estimated)
- Lead sponsor
- Fondazione IRCCS Policlinico San Matteo di PaviaUniversity, hospital or other
- Study start
- 14 Feb 2024 (actual)
- Primary completion
- 14 Mar 2026 (estimated)
- Study completion
- 14 Mar 2026 (estimated)
- First posted
- 27 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Aspergillus is a filamentous mould ubiquitous in the environment and the concentration of its spores in the air varies according to weather conditions and seasons. In this regard, efforts are often made to limit its diffusion in wards where fragile patients are housed (e.g., ICU, Haematology, Oncology, etc.). Indeed, in these patients, Aspergillus infections can present as pulmonary aspergillosis, invasive rhinosinusitis or angio-invasive aspergillosis with significantly high rates of morbidity and mortality, while it rarely causes disease in healthy immunocompetent subjects.
Previous studies have established the correlation between nasal carriage of microorganisms and the development of an invasive infectious disease; however, those studies mainly focused on Staphylococci and Candida species.
The main target of this study is to investigate the spread of Aspergillus within a hospital ward and analyse the correlation between nosocomial infection and symptom severity in a cohort of frail population.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients admitted to the Hematology ward
Key inclusion criteria (3 listed)
- ≥ 18 years old
- Signature of informed consent
- Admission to San Matteo's Hematology ward
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
number of new onset of invasive aspergillosis
Time frame: up to 2 years
number of new onset of invasive aspergillosis in patients who entered the ward with a negative swab at admission over person-time.
1 secondary outcome
correlation between the levels of Aspergillus in the air and the number of subjects with a positive swab at discharge
Time frame: up to 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Feb 2026.
Related trials for Aspergillus Infection
RecruitingObservational study
Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis
RecruitingPhase 3
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
Invasive Mold Infections
RecruitingPhase 3
Compare Oral Itraconazole and Standard Care Versus Standard Care Alone in Patients With Non-cystic Fibrosis Related Bronchiectasis With Chronic Aspergillus Infection in Reducing Bronchiectasis Exacerbations
Bronchiectasis, Bronchiectasis Adult
Not yet recruitingPhase 3
A Study of Itraconazole and Posaconazole for Chronic Pulmonary Aspergillosis
Chronic Pulmonary Aspergillosis
Not yet recruiting
Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma
Allergic Bronchopulmonary Aspergillosis, ABPA
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Aspergillus Infection, run by Fondazione IRCCS Policlinico San Matteo di Pavia at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Alba Muzzi (0382/502268, a.muzzi@smatteo.pv.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
number of new onset of invasive aspergillosis (time frame: up to 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Feb 2026.